EMERYVILLE, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today reported financial results for the quarter ended June 30, 2020.
- Total revenue of $10.6 million including four platform placements
- Completed initial public offering, raising approximately $188 million of net proceeds
Second Quarter 2020 Financial Results
Revenue was $10.6 million for the quarter ended June 30, 2020, representing a 10% decrease from the second quarter in the prior year. Product revenue was $9.1 million for the quarter, representing a 17% increase from the second quarter in the prior year. Service revenue was $1.5 million for the quarter, representing a 63% decrease from the second quarter in the prior year.
Direct platform revenue was $7.5 million for the quarter, compared to $6.9 million for the second quarter in the prior year. (Read more…) Recurring revenue was $2.9 million for the quarter, compared to $1.7 million for the second quarter in the prior year. Milestone and related revenue was $128,000 for the quarter, compared to $3.2 million for the second quarter in the prior year.
Gross profit was $7.0 million for the second quarter of 2020, down $2.6 million from $9.6 million for the corresponding prior year period. Gross margin was 66% for the second quarter of 2020, compared to 81% for the corresponding prior year period.
Operating expenses were $19.1 million for the second quarter of 2020, compared to $15.2 million in the second quarter of the prior year, representing an increase of approximately 26%.
Net loss was $12.4 million in the second quarter of 2020, compared to $6.2 million in the same period in 2019.
Cash and cash equivalents were $59.2 million as of June 30, 2020. Subsequent to the end of the quarter, on July 21, 2020, Berkeley Lights completed its initial public offering, raising approximately $188 million of net proceeds, after deducting underwriting discounts, commissions, and fees.
About Berkeley Lights
Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are for research use only. Not for use in diagnostic procedures.
Forward Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
|Three Months Ended June 30,|
|Cost of sales|
|Product cost of sales||2,384||1,949|
|Service cost of sales||1,223||242|
|Total cost of sales||3,607||2,191|
|Research and development||11,843||9,642|
|General and administrative||4,193||3,080|
|Sales and administrative||3,076||2,452|
|Total operating expenses||19,112||15,174|
|Loss from operations||(12,150||)||(5,602||)|
|Other income (expense):|
|Other income (expense), net||37||(488||)|
|Loss before income taxes||(12,422||)||(6,170||)|
|Provision for income taxes||8||15|
|Net loss and net comprehensive loss||(12,430||)||(6,185||)|
|Net loss attributable to common stockholders per share, basic and diluted||$||(4.25||)||$||(2.43||)|
|Weighted-average shares used in calculating net loss per share, basic and diluted||3,109,545||2,872,183|
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
|June 30,||December 31,|
|Cash and cash equivalents||$||59,170||$||81,033|
|Trade accounts receivable||10,236||9,334|
|Prepaid expenses and other current assets||9,061||7,799|
|Total current assets||90,375||105,347|
|Property and equipment, net||14,757||16,472|
|Operating lease right-of-use assets||13,000||7,785|
|Liabilities and shareholders’ equity|
|Trade accounts payable||$||4,270||$||3,239|
|Accrued expenses and other current liabilities||8,099||6,229|
|Current portion of notes payable||1,596||5,765|
|Total current liabilities||22,572||24,919|
|Notes payable, net of current portion||18,264||14,062|
|Deferred revenue, net of current portion||1,098||1,461|
|Lease liability, long term||11,439||6,784|
|Commitments and contingencies
|Convertible preferred stock||224,769||224,769|
|Additional paid-in capital||12,431||9,314|
|Total shareholders’ equity||66,045||83,783|
|Total liabilities and shareholders’ equity||$||119,418||$||131,009|